CN100508982C - Medicinal composition containing ceftriaxone sodium and lidocaine hydrochloride injection - Google Patents
Medicinal composition containing ceftriaxone sodium and lidocaine hydrochloride injection Download PDFInfo
- Publication number
- CN100508982C CN100508982C CNB2006101039930A CN200610103993A CN100508982C CN 100508982 C CN100508982 C CN 100508982C CN B2006101039930 A CNB2006101039930 A CN B2006101039930A CN 200610103993 A CN200610103993 A CN 200610103993A CN 100508982 C CN100508982 C CN 100508982C
- Authority
- CN
- China
- Prior art keywords
- lidocaine hydrochloride
- ceftriaxone sodium
- aseptic
- powder
- crystallization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicine composition for injection containing ceftriaxone sodium and Lidocaine Hydrochloride, and characterized by said composition contains 50mg-5000mg ceftriaxone sodium, 1mg-100mg Lidocaine Hydrochloride. The composition in said invention is prepared by split charging of germ-free ceftriaxone sodium and Lidocaine Hydrochloride in accordance with specifications.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that contains the Injectable sterile packing of ceftriaxone sodium and lidocaine hydrochloride, belong to technical field of medicine.
Background technology
Ceftriaxone sodium is the disodium salt of ceftriaxone, is long-acting, broad-spectrum antibiotic, belongs to the third generation cephalosporin class, and gram-negative bacteria and gram positive bacteria are had very strong bactericidal action, has in the serum characteristics such as long half time.It mainly has bactericidal activity by suppressing the synthetic of cell wall, and beta-lactamase (penicillinase and cephalosporinase) is had very high stability.
Ceftriaxone sodium is usually to following pathogenic bacterium performance bactericidal action:
Enterobacteriaceae lactobacteriaceae there is powerful activity.MIC to escherichia coli, Klebsiella Pneumoniae, clostridium perfringen, fluorine labor ground citrobacter, the positive Bacillus proteus of indole, Pu Luweideng Pseudomonas and Serratia
90Between 0.12-0.25mg/L.Enterobacter cloacae, acinetobacter and Pseudomonas aeruginosa are poor to the sensitivity of ceftriaxone sodium.Hemophilus influenza, Diplococcus gonorrhoeae and Neisseria meningitidis there are strong antibacterial action, Hemolytic streptococcus and streptococcus pneumoniae are also had good action.MIC to staphylococcus aureus is 2-4mg/L.The staphylococcus of methicillin-resistant and enterococcus are to the ceftriaxone sodium drug resistance.Most bacteroides fragiliss are to ceftriaxone sodium also drug resistance.Ceftriaxone sodium can extensively be distributed in each tissue and the body fluid (heart, lung, liver, biliary tract, tonsil, middle ear, nasal mucosa, skeleton, cerebrospinal fluid, Pleural fluid, prostate and synovial membrane liquid etc.).
Ceftriaxone sodium can intramuscular injection and intravenously administrable, and two kinds of route of administration have similar bactericidal effect.But can produce pain in the injection site during intramuscular injection ceftriaxone sodium.Pain is because direct chemical stimulation or administration volume cause.The local pain that injection produces can use some local anaesthetics to overcome.Lidocaine hydrochloride is a local anaesthetics commonly used, utilizes its local anesthesia analgesic effect, can prepare the painless solvent of injection, is used for the medicine of intramuscular injection pain.The medication combined use of adopting lidocaine hydrochloride injection and intramuscular injection pain is arranged in the prior art.But during as the local pain palliative, the lidocaine hydrochloride working concentration is unsuitable too high, otherwise can cause bad or other side effect of drug absorption.And owing to be subjected to the restriction of clinical regular size, lidocaine hydrochloride injection often needs further dilution or only uses certain volume, will produce some problems like this, for example, lidocaine hydrochloride is quantitatively inaccurate, liquid waste etc., and inconvenient operation is unfavorable for clinical standardized drug simultaneously.
Summary of the invention
Can dissolve rapidly with solvent for injection commonly used when the purpose of this invention is to provide a kind of the use, can satisfy the sterile powder for injection drug combination preparation of the required fixed mixing ratio that contains ceftriaxone sodium and lidocaine hydrochloride of clinical use, it promptly can ease the pain, and increases patient's toleration.Can also the standard clinical application.And two medicine in conjunction with preparation stabilization is stored, synergism is obvious.
The present invention is achieved in that
The ceftriaxone sodium and the lidocaine hydrochloride of solid forms are mixed packing with certain proportion.
Wherein the part by weight of ceftriaxone sodium and lidocaine hydrochloride is: ceftriaxone sodium is 50 parts-5000 parts, and lidocaine hydrochloride is 1 part-100 parts.
Preferably, ceftriaxone sodium is 250 parts-2000 parts, and lidocaine hydrochloride is 10 parts-80 parts.
More preferably ceftriaxone sodium is 1000 parts-2000 parts, and lidocaine hydrochloride is 40 parts-80 parts.
For every injection, wherein the content of each composition is ceftriaxone sodium 50mg-5000mg, and lidocaine hydrochloride is 1mg-100mg.
The most preferred proportioning composition of the present invention is listed in the embodiment of the invention.
The aseptic subpackaged pharmaceutical composition of ceftriaxone for inj of the present invention and lidocaine hydrochloride can adopt following method preparation: the ceftriaxone sodium aseptic powder and the lidocaine hydrochloride aseptic powder of recipe quantity are placed sterile chamber, use mixed powder machinery to carry out aseptic mixed powder, be sub-packed in the antibiotic glass bottle.
The present invention also can add pharmaceutical excipient as required, as mannitol, sorbitol, sodium chloride, glucose, fructose, sucrose, xylitol, lactose and dextran.These pharmaceutical excipients help out, and its adding method and addition are the galenic pharmacy routine techniques.
The present invention uses aseptic raw material ceftriaxone sodium and lidocaine hydrochloride, tackles ceftriaxone sodium and the lidocaine hydrochloride raw material bought on the market in case of necessity and carries out the sterile-processed processing.
The preferred lyase method for crystallising of the acquisition of aseptic ceftriaxone sodium raw materials used in the present invention also can obtain by lyophilization or other proper method.
The preferred lyase crystallization process of the acquisition of aseptic lidocaine hydrochloride raw material used in the present invention.Also can obtain by lyophilization or other proper method.
Through the inventive method, raw material particularly of the present invention is handled through aseptic process method of the present invention, adopts the ceftriaxone sodium and the lidocaine hydrochloride of solid form, has made the Injectable sterile powder preparation of fixed mixing ratio of the present invention.
The sterile packaged preparation that contains ceftriaxone sodium and lidocaine hydrochloride of the present invention that makes with the embodiment of the invention 1 is carried out stability experiment, and condition is: put illumination (illumination 4500 ± 500L respectively
x) and high temperature (60 ℃) condition under placed 10 days, and measured, mainly quality index study on the stability data such as following table 1-2 in the 5th day and the 10th day.
Table 1 sterile packaged preparation of ceftriaxone sodium and lidocaine hydrochloride that contains of the present invention is at illumination (4500 ± 500L
x) stable down
| Project | 0 day | 5 days | 10 days |
| Appearance character | The off-white color crystalline powder | The off-white color crystalline powder | The off-white color crystalline powder |
| Clarity | Qualified | Qualified | Qualified |
| Ceftriaxone sodium related substance (%) | 0.34 | 0.47 | 0.66 |
| Lidocaine hydrochloride related substance (%) | 0.21 | 0.38 | 0.57 |
| The ceftriaxone sodium content is (in ceftriaxone, %) | 99.8 | 99.6 | 99.4 |
| Lidocaine hydrochloride content (%) | 99.5 | 99.3 | 98.8 |
Table 2 stability of sterile packaged preparation under high temperature (60 ℃) that contains ceftriaxone sodium and lidocaine hydrochloride of the present invention
| Project | 0 day | 5 days | 10 days |
| Appearance character | The off-white color crystalline powder | The off-white color crystalline powder | The off-white color crystalline powder |
| Clarity | Qualified | Qualified | Qualified |
| Ceftriaxone sodium related substance (%) | 0.34 | 0.58 | 0.83 |
| Lidocaine hydrochloride related substance (%) | 0.21 | 0.42 | 0.56 |
| The ceftriaxone sodium content is (in ceftriaxone, %) | 99.8 | 99.2 | 98.7 |
| Lidocaine hydrochloride content (%) | 99.5 | 99.2 | 99.1 |
The sterile packaged preparation that contains ceftriaxone sodium and lidocaine hydrochloride of the present invention that embodiment 1 is made, put under 40 ℃ ± 2 ℃, the accelerated test condition of relative humidity 75% ± 5% and investigate 6 months, respectively at the 1st, 2,3 with measure main quality index study on the stability data such as following table 36 months the time.
Table 3 (40+2 ℃, 75 ± 5%RH) stability of sterile packaged preparation under the accelerated test condition that contain ceftriaxone sodium and lidocaine hydrochloride of the present invention
| Project | 0 month | January | February | March | June |
| Appearance character | The off-white color crystalline powder | The off-white color crystalline powder | The off-white color crystalline powder | The off-white color crystalline powder | The off-white color crystalline powder |
| Clarity | Qualified | Qualified | Qualified | Qualified | Qualified |
| Ceftriaxone sodium related substance (%) | 0.34 | 0.41 | 0.56 | 0.68 | 0.82 |
| Lidocaine hydrochloride related substance (%) | 0.21 | 0.35 | 0.42 | 0.54 | 0.67 |
| The ceftriaxone sodium content is (in ceftriaxone, %) | 99.8 | 99.7 | 99.4 | 99.1 | 98.8 |
| Lidocaine hydrochloride content (%) | 99.5 | 99.4 | 99.1 | 98.8 | 98.6 |
By above result as seen, the Injectable sterile packing drug combination preparation of ceftriaxone sodium and lidocaine hydrochloride that contains of the present invention is through above-mentioned experimental condition, main quality investigation index does not all take place obviously to change, prescription and technology that preparation is described are reasonable, stable, can satisfy need of industrial production.
The advantage of ceftriaxone sodium of the present invention and the aseptic subpackaged drug combination preparation of lidocaine hydrochloride is, constant product quality is controlled, with common solvent for injection dissolving commonly used (as water for injection, or nutrition infusion preparation), can use during clinical use.Proportioning of the present invention is fixed, and preparation technology is simple, and is clinical easy to use, can reduce and produce and drug cost.Can ease the pain, increase patient's toleration.Can also the standard clinical application.
The specific embodiment
Below will the invention will be further described by embodiment, these descriptions are not that content of the present invention is done further to limit.One skilled in the art will understand that to be equal to replacement to what content of the present invention was done, or corresponding the improvement, still belong within protection scope of the present invention.
Embodiment 1
Prescription:
Ceftriaxone sodium 250g
Lidocaine hydrochloride aseptic powder 10g
Make 1000
Preparation technology
1. get the about 14g of lidocaine hydrochloride coarse raw materials, be dissolved in the 21ml dehydrated alcohol, (W/V) active carbon of adding 0.1% stirs decolouring, through carbon removal filtration and aseptic filtration, filtrate adds ether 420ml down in 5-10 ℃ of stirring (30-35r/min), leave standstill then to crystallization and separate out fully, filter, crystallization is washed with ether, filter is done, and puts the cold drying of reducing pressure in the vacuum drying oven and promptly gets the lidocaine hydrochloride aseptic powder
2. the ceftriaxone sodium and the lidocaine hydrochloride aseptic powder of getting above-mentioned recipe quantity place sterile chamber, use mixed powder machinery to carry out aseptic mixed powder, are sub-packed in the antibiotic glass bottle.
Embodiment 2
Prescription:
Ceftriaxone sodium 500g
Lidocaine hydrochloride aseptic powder 20g
Make 1000
Preparation technology
1. get the about 27g of lidocaine hydrochloride coarse raw materials, be dissolved in the 41ml dehydrated alcohol, (W/V) active carbon of adding 0.1% stirs decolouring, through carbon removal filtration and aseptic filtration, filtrate adds ether 820ml down in 5-10 ℃ of stirring (30-35r/min), leave standstill then to crystallization and separate out fully, filter, crystallization is washed with ether, filter is done, and puts the cold drying of reducing pressure in the vacuum drying oven and promptly gets the lidocaine hydrochloride aseptic powder.
2. the ceftriaxone sodium and the lidocaine hydrochloride aseptic powder of getting above-mentioned recipe quantity place sterile chamber, use mixed powder machinery to carry out aseptic mixed powder, are sub-packed in the antibiotic glass bottle.
Embodiment 3
Prescription:
Ceftriaxone sodium 1000g
Lidocaine hydrochloride aseptic powder 40g
Make 1000
Preparation technology
1.1. get the about 50g of lidocaine hydrochloride coarse raw materials, be dissolved in the 75ml dehydrated alcohol, (W/V) active carbon of adding 0.1% stirs decolouring, through carbon removal filtration and aseptic filtration, filtrate adds ether 1500ml down in 5-10 ℃ of stirring (30-35r/min), leave standstill then to crystallization and separate out fully, filter, crystallization is washed with ether, filter is done, and puts the cold drying of reducing pressure in the vacuum drying oven and promptly gets the lidocaine hydrochloride aseptic powder.
2. the ceftriaxone sodium and the lidocaine hydrochloride aseptic powder of getting above-mentioned recipe quantity place sterile chamber, use mixed powder machinery to carry out aseptic mixed powder, are sub-packed in the antibiotic glass bottle.
Embodiment 4
Prescription:
Ceftriaxone sodium 2000g
Lidocaine hydrochloride aseptic powder 80g
Make 1000
Preparation technology
1.1. get the about 95g of lidocaine hydrochloride coarse raw materials, be dissolved in the 145ml dehydrated alcohol, (W/V) active carbon of adding 0.1% stirs decolouring, through carbon removal filtration and aseptic filtration, filtrate adds ether 3000ml down in 5-10 ℃ of stirring (30-35r/min), leave standstill then to crystallization and separate out fully, filter, crystallization is washed with ether, filter is done, and puts the cold drying of reducing pressure in the vacuum drying oven and promptly gets the lidocaine hydrochloride aseptic powder.
2. the ceftriaxone sodium and the lidocaine hydrochloride aseptic powder of getting above-mentioned recipe quantity place sterile chamber, use mixed powder machinery to carry out aseptic mixed powder, are sub-packed in the antibiotic glass bottle.
Embodiment 5
Prescription:
Ceftriaxone sodium 500g
Lidocaine hydrochloride aseptic powder 20g
Make 1000
Preparation technology
1. prepare the lidocaine hydrochloride aseptic powder.
(1) the 30g lidocaine hydrochloride is put in the sterile chamber, add pharmaceutically acceptable water soluble excipient in case of necessity, as one or more the about 45g in mannitol, sorbitol, sodium chloride, glucose, fructose, sucrose, xylitol, lactose and the dextran, the water for injection that adds 480ml, stirring and dissolving.
(2) medicinal charcoal of adding 0.02%-0.08%, stirring and adsorbing 15-30 minute.Filtering with microporous membrane with Φ 0.45 μ m takes off charcoal.The filtrate 600ml that adds to the full amount of water for injection.
(3) medicinal liquid injects the rustless steel pallet with the microporous filter membrane fine straining of Φ 0.22 μ m with filtrate, and thickness is about 1.0-1.5cm.
(4) medicinal liquid is carried out lyophilization, then freeze-dried products is taken out and pulverized 100 mesh sieves, promptly get the lidocaine hydrochloride aseptic powder.
2. the ceftriaxone sodium and the lidocaine hydrochloride aseptic powder of getting recipe quantity place sterile chamber, use mixed powder machinery to carry out aseptic mixed powder, are sub-packed in the antibiotic glass bottle.
Claims (1)
1, a kind of medicinal composition for injections that contains ceftriaxone sodium and lidocaine hydrochloride is characterized in that,
Preparation method
(1) gets the about 14g of lidocaine hydrochloride coarse raw materials, be dissolved in the 21ml dehydrated alcohol, (W/V) active carbon of adding 0.1% stirs decolouring, through carbon removal filtration and aseptic filtration, filtrate is stirred at 5-10 ℃ and is added ether 420ml under the 30-35r/min, leave standstill then to crystallization and separate out fully, filter, crystallization is washed with ether, filter is done, and puts the cold drying of reducing pressure in the vacuum drying oven and promptly gets the lidocaine hydrochloride aseptic powder;
(2) ceftriaxone sodium and the lidocaine hydrochloride aseptic powder of getting above-mentioned recipe quantity places sterile chamber, uses to mix powder machinery and carry out aseptic mixed powder, is sub-packed in the antibiotic glass bottle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006101039930A CN100508982C (en) | 2006-06-09 | 2006-08-07 | Medicinal composition containing ceftriaxone sodium and lidocaine hydrochloride injection |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610082809 CN1857225A (en) | 2006-06-09 | 2006-06-09 | Aseptic injection preparation containing ceftriaxone sodium and lidocaine hydrochloride |
| CN200610082809.9 | 2006-06-09 | ||
| CNB2006101039930A CN100508982C (en) | 2006-06-09 | 2006-08-07 | Medicinal composition containing ceftriaxone sodium and lidocaine hydrochloride injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1943578A CN1943578A (en) | 2007-04-11 |
| CN100508982C true CN100508982C (en) | 2009-07-08 |
Family
ID=38043372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006101039930A Expired - Fee Related CN100508982C (en) | 2006-06-09 | 2006-08-07 | Medicinal composition containing ceftriaxone sodium and lidocaine hydrochloride injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100508982C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552275B (en) * | 2012-01-17 | 2013-06-26 | 山东罗欣药业股份有限公司 | Injection powder and injection preparation of cefoperazone sodium-tazobactam combination |
| CN103446058A (en) * | 2013-09-09 | 2013-12-18 | 海南永田药物研究院有限公司 | Pharmaceutical composition consisting of ceftriaxone sodium for injection and 1% lidocaine hydrochloride injection |
| CN104382864A (en) * | 2014-08-29 | 2015-03-04 | 四川制药制剂有限公司 | Processing technology of ceftriaxone sodium for injection |
-
2006
- 2006-08-07 CN CNB2006101039930A patent/CN100508982C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1943578A (en) | 2007-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104644640B (en) | A kind of preparation method of cefoperazone sodium and sulbactam sodium for injection powder pin | |
| Wiseman et al. | Cefprozil: a review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential | |
| CN102144975B (en) | Cefprozil suspension pharmaceutical composition | |
| CN100508982C (en) | Medicinal composition containing ceftriaxone sodium and lidocaine hydrochloride injection | |
| CN1857225A (en) | Aseptic injection preparation containing ceftriaxone sodium and lidocaine hydrochloride | |
| CN102755325B (en) | Cefoxitin sodium medicinal composition, powder injection and preparation method thereof | |
| CN102327270B (en) | Beta-lactam compound antibiotic composition | |
| CN101143146A (en) | Cefoperazone sodium and sulbactam sodium composition | |
| CN101249092A (en) | Infection contamination resistance pharmaceutical combination containing optimum proportioning cefoperazone natrium and sulbactam sodium and method of preparing the same | |
| CN103622916B (en) | Cefixime dry suspension and preparation method thereof | |
| CN103520120B (en) | A kind of L-084 composition granule | |
| CN101890022A (en) | Cefoperazone sodium and tazobactam sodium medicament composition liposome injection | |
| CN102688183A (en) | Stable moxifloxacin hydrochloride injection | |
| CN108066338A (en) | New antibiotic composition when prevention and treatment aerobic bacteria and anaerobic bacteria mixed infection and preparation method thereof | |
| CN103432076A (en) | Cefprozil dry suspension and preparation method thereof | |
| JPH0214058B2 (en) | ||
| CN103655460B (en) | Injection medicinal composition containing aztreonam, as well as preparation method and application thereof | |
| CN102743390B (en) | cefepime hydrochloride medicine composition, powder-injection thereof and preparation method thereof | |
| CN103040818B (en) | Drug composition containing amoxicillin sodium and clavulanate potassium compound | |
| CN101816669B (en) | Composition containing gentamicin and borneol and use thereof | |
| CN103622933B (en) | Cefdinir capsule and preparation method thereof | |
| CN102462683B (en) | Antibiotic composition and preparation method and application thereof | |
| CN103585119A (en) | Stabilization preparation containing epoprostenol and medical salt of epoprostenol and preparation method of stabilization preparation | |
| CN102670620B (en) | Cefradine-borneol composition | |
| CN103191067A (en) | Freeze-dried powder injection of bromhexine hydrochloride and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090708 Termination date: 20110807 |